This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Pediatric Vaccine Market

Market Insights on Pediatric Vaccine covering sales outlook, demand forecast & up-to-date key trends

Pediatric Vaccine Market By Technology Type (Toxoid Vaccine, Conjugate Vaccine, Subunit Vaccine), End User (Hospital Pharmacies, Retail Pharmacies, Institutional Health Centres), Indication (Polio Vaccine, Rotavirus Vaccine, MMR Vaccine) & Region - Forecast to 2016 - 2026

Global Pediatric Vaccine Market: Towards a better and safer tomorrow

Pediatric vaccines are administered to a child in its pediatric age which is from 0 – 18 years of age. Vaccines are generally given in order to prevent children from diseases transferred through infections, seasonal variations and even through unhygienic areas. Depending upon disease, the vaccines are administered at regular intervals.  WHO has designed a standard immunization program in order to have desired time interval between vaccines doses.

Pediatric vaccines considered in the report include pneumococcal vaccine, DTP vaccine, rotavirus vaccine, MMR vaccine, polio vaccine, influenza vaccine, hepatitis B vaccine, Hib vaccine and meningococcal vaccine. Pneumococcal vaccine is administered to prevent the child from infectious diseases such as pneumonia. DTP vaccines is a combination vaccine administered against prevention of three diseases those are diphtheria, tetanus and pertussis. Hib vaccine is also a combination vaccine for hepatitis B and influenza and is widely accepted.

Customize this Report

Let us know your requirement to get
100% FREE customization

The market to expand manifold during the forecast period (2016 - 2026)

In terms of revenue, the global pediatric vaccine market is projected to expand at a CAGR of 12.2% during the forecast period and is expected to be valued at US$ 88.14 Bn by the end of 2026.

Pediatric Vaccine Market Download Report Brochure

Revamped government policies to benefit the market, though soaring prices of vaccines to play spoilsport

The growth of the global pediatric vaccine market is primarily driven by increasing awareness regarding benefits of vaccination in prevention of diseases, rising economic growth, the collaboration of national manufacturers with key players in view to provide high-quality vaccines in at remote areas and initiative by global key players in developing innovative vaccines.

In addition favourable reimbursement and increasing government support is expected to fuel the market growth over the forecast period. However, rising cost of vaccines, low accessibility to remote areas and increasing the availability of biosimilars at low rates might hinder the market growth over the forecast period.

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

The Pneumococcal segment to act as a catalyst in the overall market growth

Based on indication, the global pediatric vaccine market is segmented into pneumococcal vaccine, DTP vaccine, rotavirus vaccine, MMR vaccine, polio vaccine, influenza vaccine, hepatitis B vaccine, Hib vaccine and meningococcal vaccine. In terms of revenue share, the pneumococcal segment dominated the global pediatric vaccine market in 2015 and is expected to reach the cusp within the forecast period. The Hib segment is expected to witness relatively higher growth rates in terms of value in the global paediatric vaccine market over the forecast period.

Recombinant segment to face steep competition from the Conjugate segment within the forecast period

Based on technology, the global pediatric vaccine market is segmented into live or attenuated vaccine, inactivated or killed vaccines, conjugate vaccine, toxoid vaccine, subunit vaccine and recombinant vaccine. In terms of revenue share, the conjugate segment dominated the global paediatric vaccine market in 2015 and is expected to maintain the spike throughout the forecast period, registering higher CAGR as compared to the recombinant segment.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Monovalent vaccine segment to accumulate maximum market share

Based on vaccine type, the global pediatric vaccine market is segmented into monovalent vaccines and multivalent vaccines. Among these, monovalent vaccine segment held maximum market share in 2015 and expected to continue the trend throughout the forecast period.

The Institutional Health Centres segment to topple Hospital Pharmacy segment in the forecast period

Based on end user, the global paediatric vaccine market is segmented into hospital pharmacies, retail pharmacies and institutional health centres. Currently, institutional health centres segment accounts for relatively higher revenue share, followed by hospital pharmacy end user segment.

North America market to lead the pack

The global paediatric vaccine market is segmented into seven major regions: North America, Latin America, Western Europe, Eastern Europe, APEJ (Asia Pacific excluding Japan), Japan and the Middle East & Africa (MEA). In terms of value, North America is expected to be the dominant regional market by 2016 end and is expected to expand at a CAGR of 11.0% over the forecast period. APEJ is expected to be the fastest growing market in terms of revenue growth in the global paediatric vaccine market, registering a CAGR of 14.9% over the forecast period.

Key stakeholders to create clamour in the market through mergers and revamped investment policies

Some key players in the global pediatric vaccine market included in this report are

  • GlaxoSmithKline Plc
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Sanofi
  • Panacea Biotec
  • Zydus Cadila
  • Emergent BioSolutions Inc.
  • Serum Institute of India Pvt. Ltd.
  • Bharat Biotech and Indian Immunologicals Ltd.

Market Segmentation

Region

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • APEJ
  • MEA
  • Japan

Technology

  • Live or Attenuated Vaccine
  • Inactivated or Killed Vaccine
  • Toxoid Vaccine
  • Conjugate Vaccine
  • Subunit Vaccine
  • Recombinant Vector Vaccine

Indication

  • Pneumococcal Conjugate Vaccine
  • DTP Vaccine
  • Influenza
  • Meningococcal Vaccine
  • Polio Vaccine
  • Rotavirus Vaccine
  • MMR Vaccine
  • Varicella Virus Vaccine

End User

  • Hospital Pharmacies
  • Retail Pharmacies
  • Institutional Health Centres

Vaccine Type

  • Monovalent Vaccines
  • Multivalent Vaccines

Frequently Asked Questions

The pediatric vaccine market is likely to secure a CAGR of 12.2% through 2032.

The size of pediatric vaccine market is estimated to cross US$ 175.86 million by 2032.

The pediatric vaccine market is likely to record a value of US$ 55.62 billion in 2022.

North America is likely to lead the pediatric vaccine market.

Table of Content

1. Executive Summary

2. Market Introduction

   2.1. Market Definition

   2.2. Market Taxonomy

   2.3. Parent / Associated Market Overview

3. Global Paediatric Vaccine Market Analysis Scenario

   3.2. Market Size (US$ Mn) and Forecast

      3.2.1. Market Size and Y-o-Y Growth

      3.2.2. Absolute $ Opportunity

   3.3. Market Overview

      3.3.1. Value Chain

4. Market Dynamics

   4.1. Macro-economic Factors

   4.2. Drivers

      4.2.1. Supply Side

      4.2.2. Demand Side

   4.3. Restraints

   4.4. Opportunity

   4.5. Forecast Factors – Relevance and Impact

   4.6. Key Industry Events

   4.7. PESTLE Analysis

5. Global Paediatric Vaccine Market Analysis and Forecasts, By Indication 

   5.1. Introduction

   5.2. Basis Point Share (BPS) Analysis By Indication Type

   5.3. Y-o-Y Growth Projections By Indication Type

   5.4. Market Value (US$ Mn) Forecast By Indication, 2016–2026

      5.4.1. Pneumococcal vaccine

      5.4.2. DTP vaccine

      5.4.3. Rotavirus vaccine 

      5.4.4. MMR vaccine

      5.4.5. Polio vaccine

      5.4.6. Influenza vaccine 

      5.4.7. Hepatitis B vaccine

      5.4.8. Meningococcal vaccine

      5.4.9. Hib vaccine

      5.4.10. Varicella vaccine 

   5.5. Prominent Trends

   5.6. Market Attractiveness By Indication 

6. Global Paediatric Vaccine Market Analysis and Forecasts, By Technology 

   6.1. Introduction

   6.2. Basis Point Share (BPS) Analysis By Technology 

   6.3. Y-o-Y Growth Projections By Technology

   6.4. Market Value (US$ Mn) Forecast By Technology, 2016–2026

      6.4.1. Live or attenuated vaccine

         6.4.1.6. Inactivated or killed vaccine

         6.4.2.3. Toxoid vaccine

         6.4.3.3. Conjugate Vaccine

         6.4.4.3. Subunit vaccine

         6.4.4.4. Recombinant vaccine

   6.5. Prominent Trends

   6.6. Market Attractiveness By Technology

7. Global Paediatric Vaccine Market Analysis and Forecasts, By Vaccine Type 

   7.1. Introduction

   7.2. Basis Point Share (BPS) Analysis By Vaccine Type 

   7.3. Y-o-Y Growth Projections By Vaccine Type 

   7.4. Market Value (US$ Mn) Forecast By Vaccine Type, 2016–2026

      7.4.1. Monovalent vaccine

      7.4.2. Mulitvalent vaccine 

   7.5. Prominent Trends

   7.6. Market Attractiveness By Vaccine Type 

8. Global Paediatric Vaccine Market Analysis and Forecasts, By End Users 

   8.1. Introduction

   8.2. Basis Point Share (BPS) Analysis By End Users 

   8.3. Y-o-Y Growth Projections By End Users 

   8.4. Market Value (US$ Mn) Forecast By End Users, 2016–2026

      8.4.1. Hospital Pharmacies 

      8.4.2. Retail pharmacies 

      8.4.3. Institutional health centers 

   8.5. Prominent Trends

   8.6. Market Attractiveness By End Users 

9. Global Paediatric Vaccine Market Analysis and Forecasts, By Region

   9.1. Basis Point Share (BPS) Analysis By Region

   9.2. Y-o-Y Growth Projections By Region

   9.3. Market Value (US$ Mn) Forecast By Region

      9.3.1. North America 

      9.3.2. Latin America 

      9.3.3. Western Europe 

      9.3.4. Eastern Europe 

      9.3.5. APEJ 

      9.3.6. Japan 

      9.3.7. MEA 

   9.4. Market Attractiveness By Region

10. North America Paediatric Vaccine Market Analysis and Forecast

   10.1.Introduction

      10.1.1. Basis Point Share (BPS) Analysis By Country

      10.1.2. Y-o-Y Growth Projections By Country

   10.2.Market Value (US$ Mn) Forecast By Indication, 2016–2026

      10.2.1. Pneumococcal vaccine

      10.2.2. DTP vaccine

      10.2.3. Rotavirus vaccine 

      10.2.4. MMR vaccine

      10.2.5. Polio vaccine

      10.2.6. Influenza vaccine 

      10.2.7. Hepatitis B vaccine

      10.2.8. Meningococcal vaccine

      10.2.9. Hib vaccine

      10.2.10. Varicella vaccine 

   10.3.Market Value (US$ Mn) Forecast By Technology, 2016–2026

      10.3.1. Live or attenuated vaccine

         10.3.1.1. Inactivated or killed vaccine

         10.3.1.2. Toxoid vaccine

         10.3.1.3. Conjugate Vaccine

         10.3.1.4. Subunit vaccine

         10.3.1.5. Recombinant vaccine

   10.4.Market Value (US$ Mn) Forecast By Vaccine Type, 2016–2026

      10.4.1. Monovalent vaccine

      10.4.2. Mulitvalent vaccine 

   10.5.Market Value (US$ Mn) Forecast By End Users, 2016–2026

      10.5.1. Hospital Pharmacies 

      10.5.2. Retail pharmacies 

      10.5.3. Institutional health centers 

   10.6.Market Value (US$ Mn) Forecast By Country, 2016–2026

      10.6.1. US

      10.6.2. Canada

   10.7.Market Attractiveness Analysis 

      10.7.1. By Indication 

      10.7.2. By Technology

      10.7.3. By Vaccine Type 

      10.7.4. By End Users 

      10.7.5. By Country

   10.8. Prominent Trends 

   10.9. Drivers and Restraints: Impact Analysis 

11. Latin America Paediatric Vaccine Market Analysis and Forecast

   11.1.Introduction

      11.1.1. Basis Point Share (BPS) Analysis By Country

      11.1.2. Y-o-Y Growth Projections By Country

      11.1.3. Key Regulations

   11.2.Market Value (US$ Mn) Forecast By Indication, 2016–2026

      11.2.1. Pneumococcal vaccine

      11.2.2. DTP vaccine

      11.2.3. Rotavirus vaccine 

      11.2.4. MMR vaccine

      11.2.5. Polio vaccine

      11.2.6. Influenza vaccine 

      11.2.7. Hepatitis B vaccine

      11.2.8. Meningococcal vaccine

      11.2.9. Hib vaccine

      11.2.10. Varicella vaccine 

   11.3.Market Value (US$ Mn) Forecast By Technology, 2016–2026

      11.3.1. Live or attenuated vaccine

         11.3.1.1. Inactivated or killed vaccine

         11.3.1.2. Toxoid vaccine

         11.3.1.3. Conjugate Vaccine

         11.3.1.4. Subunit vaccine

         11.3.1.5. Recombinant vaccine

   11.4.Market Value (US$ Mn) Forecast By Vaccine Type, 2016–2026

      11.4.1. Monovalent vaccine

      11.4.2. Mulitvalent vaccine 

   11.5.Market Value (US$ Mn) Forecast By End Users, 2016–2026

      11.5.1. Hospital Pharmacies 

      11.5.2. Retail pharmacies 

      11.5.3. Institutional health centers 

   11.6.Market Value (US$ Mn) Forecast By Country, 2016–2026

      11.6.1. Brazil

      11.6.2. Mexico

      11.6.3. Rest of Latin America

   11.7.Market Attractiveness Analysis 

      11.7.1. By Indication 

      11.7.2. By Technology

      11.7.3. By Vaccine Type 

      11.7.4. By End Users 

      11.7.5. By Country

   11.8. Prominent Trends 

   11.9. Drivers and Restraints: Impact Analysis 

12. Western Europe Paediatric Vaccine Market Analysis and Forecast

   12.1.Introduction

      12.1.1. Basis Point Share (BPS) Analysis By Country

      12.1.2. Y-o-Y Growth Projections By Country

      12.1.3. Key Regulations

   12.2.Market Value (US$ Mn) Forecast By Indication, 2016–2026

      12.2.1. Pneumococcal vaccine

      12.2.2. DTP vaccine

      12.2.3. Rotavirus vaccine 

      12.2.4. MMR vaccine

      12.2.5. Polio vaccine

      12.2.6. Influenza vaccine 

      12.2.7. Hepatitis B vaccine

      12.2.8. Meningococcal vaccine

      12.2.9. Hib vaccine

      12.2.10. Varicella vaccine 

   12.3.Market Value (US$ Mn) Forecast By Technology, 2016–2026

      12.3.1. Live or attenuated vaccine

         12.3.1.1. Inactivated or killed vaccine

         12.3.1.2. Toxoid vaccine

         12.3.1.3. Conjugate Vaccine

         12.3.1.4. Subunit vaccine

         12.3.1.5. Recombinant vaccine

   12.4.Market Value (US$ Mn) Forecast By Vaccine Type, 2016–2026

      12.4.1. Monovalent vaccine

      12.4.2. Mulitvalent vaccine 

   12.5.Market Value (US$ Mn) Forecast By End Users, 2016–2026

      12.5.1. Hospital Pharmacies 

      12.5.2. Retail pharmacies 

      12.5.3. Institutional health centers 

   12.6.Market Value (US$ Mn) Forecast By Country, 2016–2026

      12.6.1. UK

      12.6.2. France

      12.6.3. Germany

      12.6.4. Italy

      12.6.5. Spain

      12.6.6. Benelux

      12.6.7. Rest of Western Europe

   12.7.Market Attractiveness Analysis 

      12.7.1. By Indication 

      12.7.2. By Technology

      12.7.3. By Vaccine Type 

      12.7.4. By End Users 

      12.7.5. By Country

   12.8. Prominent Trends 

   12.9. Drivers and Restraints: Impact Analysis 

13. Eastern Europe Paediatric Vaccine Market Analysis and Forecast

   13.1.Introduction

      13.1.1. Basis Point Share (BPS) Analysis By Country

      13.1.2. Y-o-Y Growth Projections By Country

      13.1.3. Key Regulations

   13.2.Market Value (US$ Mn) Forecast By Indication, 2016–2026

      13.2.1. Pneumococcal vaccine

      13.2.2. DTP vaccine

      13.2.3. Rotavirus vaccine 

      13.2.4. MMR vaccine

      13.2.5. Polio vaccine

      13.2.6. Influenza vaccine 

      13.2.7. Hepatitis B vaccine

      13.2.8. Meningococcal vaccine

      13.2.9. Hib vaccine

      13.2.10. Varicella vaccine 

   13.3.Market Value (US$ Mn) Forecast By Technology, 2016–2026

      13.3.1. Live or attenuated vaccine

      13.3.1.1. Inactivated or killed vaccine

      13.3.1.2. Toxoid vaccine

      13.3.1.3. Conjugate Vaccine

      13.3.1.4. Subunit vaccine

      13.3.1.5. Recombinant vaccine

   13.4.Market Value (US$ Mn) Forecast By Vaccine Type, 2016–2026

      13.4.1. Monovalent vaccine

      13.4.2. Mulitvalent vaccine 

   13.5.Market Value (US$ Mn) Forecast By End Users, 2016–2026

      13.5.1. Hospital Pharmacies 

      13.5.2. Retail pharmacies 

      13.5.3. Institutional health centers 

   13.6.Market Value (US$ Mn) Forecast By Country, 2016–2026

      13.6.1. Russia

      13.6.2. Poland

      13.6.3. Rest of Eastern Europe

   13.7.Market Attractiveness Analysis 

      13.7.1. By Indication 

      13.7.2. By Technology

      13.7.3. By Vaccine Type 

      13.7.4. By End Users 

      13.7.5. By Country

   13.8. Prominent Trends 

   13.9. Drivers and Restraints: Impact Analysis 

14. APEJ Paediatric Vaccine Market Analysis and Forecast

   14.1.Introduction

      14.1.1. Basis Point Share (BPS) Analysis By Country

      14.1.2. Y-o-Y Growth Projections By Country

      14.1.3. Key Regulations

   14.2.Market Value (US$ Mn) Forecast By Indication, 2016–2026

      14.2.1. Pneumococcal vaccine

      14.2.2. DTP vaccine

      14.2.3. Rotavirus vaccine 

      14.2.4. MMR vaccine

      14.2.5. Polio vaccine

      14.2.6. Influenza vaccine 

      14.2.7. Hepatitis B vaccine

      14.2.8. Meningococcal vaccine

      14.2.9. Hib vaccine

      14.2.10. Varicella vaccine 

   14.3.Market Value (US$ Mn) Forecast By Technology, 2016–2026

      14.3.1. Live or attenuated vaccine

         14.3.1.1. Inactivated or killed vaccine

         14.3.1.2. Toxoid vaccine

         14.3.1.3. Conjugate Vaccine

         14.3.1.4. Subunit vaccine

         14.3.1.5. Recombinant vaccine

   14.4.Market Value (US$ Mn) Forecast By Vaccine Type, 2016–2026

      14.4.1. Monovalent vaccine

      14.4.2. Mulitvalent vaccine 

   14.5.Market Value (US$ Mn) Forecast By End Users, 2016–2026

      14.5.1. Hospital Pharmacies 

      14.5.2. Retail pharmacies 

      14.5.3. Institutional health centers 

   14.6.Market Value (US$ Mn) Forecast By Country, 2016–2026

      14.6.1. China

      14.6.2. India

      14.6.3. Australia & New Zealand

      14.6.4. ASEAN

      14.6.5. Rest of APEJ

   14.7.Market Attractiveness Analysis 

      14.7.1. By Indication 

      14.7.2. By Technology

      14.7.3. By Vaccine Type 

      14.7.4. By End Users 

      14.7.5. By Country

   14.8. Prominent Trends 

   14.9. Drivers and Restraints: Impact Analysis 

15. Japan Paediatric Vaccine Market Analysis and Forecast

   15.1.Introduction

      15.1.1. Basis Point Share (BPS) Analysis By Country

      15.1.2. Y-o-Y Growth Projections By Country

   15.2.Market Value (US$ Mn) Forecast By Indication, 2016–2026

      15.2.1. Pneumococcal vaccine

      15.2.2. DTP vaccine

      15.2.3. Rotavirus vaccine 

      15.2.4. MMR vaccine

      15.2.5. Polio vaccine

      15.2.6. Influenza vaccine 

      15.2.7. Hepatitis B vaccine

      15.2.8. Meningococcal vaccine

      15.2.9. Hib vaccine

      15.2.10. Varicella vaccine 

   15.3.Market Value (US$ Mn) Forecast By Vaccine Type, 2016–2026

      15.3.1. Live or attenuated vaccine

         15.3.1.1. Inactivated or killed vaccine

         15.3.1.2. Toxoid vaccine

         15.3.1.3. Conjugate Vaccine

         15.3.1.4. Subunit vaccine

         15.3.1.5. Recombinant vaccine

   15.4.Market Value (US$ Mn) Forecast By Vaccine Type, 2016–2026

      15.4.1. Monovalent vaccine

      15.4.2. Mulitvalent vaccine 

   15.5.Market Value (US$ Mn) Forecast By End Users, 2016–2026

      15.5.1. Hospital Pharmacies 

      15.5.2. Retail pharmacies 

      15.5.3. Institutional health centers 

   15.6.Market Attractiveness Analysis 

      15.6.1. By Indication 

      15.6.2. By Vaccine Type 

      15.6.3. By Vaccine Type 

      15.6.4. By End Users 

   15.7. Prominent Trends 

   15.8. Drivers and Restraints: Impact Analysis 

16. MEA Paediatric Vaccine Market Analysis and Forecast

   16.1.Introduction

      16.1.1. Basis Point Share (BPS) Analysis By Country

      16.1.2. Y-o-Y Growth Projections By Country

      16.1.3. Key Regulations

   16.2.Market Value (US$ Mn) Forecast By Indication, 2016–2026

      16.2.1. Pneumococcal vaccine

      16.2.2. DTP vaccine

      16.2.3. Rotavirus vaccine 

      16.2.4. MMR vaccine

      16.2.5. Polio vaccine

      16.2.6. Influenza vaccine 

      16.2.7. Hepatitis B vaccine

      16.2.8. Meningococcal vaccine

      16.2.9. Hib vaccine

      16.2.10. Varicella vaccine 

   16.3.Market Value (US$ Mn) Forecast By Technology, 2016–2026

      16.3.1. Live or attenuated vaccine

         16.3.1.1. Inactivated or killed vaccine

         16.3.1.2. Toxoid vaccine

         16.3.1.3. Conjugate Vaccine

         16.3.1.4. Subunit vaccine

         16.3.1.5. Recombinant vaccine

   16.4.Market Value (US$ Mn) Forecast By Vaccine Type, 2016–2026

      16.4.1. Monovalent vaccine

      16.4.2. Mulitvalent vaccine 

   16.5.Market Value (US$ Mn) Forecast By End Users, 2016–2026

      16.5.1. Hospital Pharmacies 

      16.5.2. Retail pharmacies 

      16.5.3. Institutional health centers 

   16.6.Market Value (US$ Mn) Forecast By Country, 2016–2026

      16.6.1. GCC Countries

      16.6.2. South Africa

      16.6.3. Rest of MEA

   16.7.Market Attractiveness Analysis 

      16.7.1. By Indication 

      16.7.2. By Technology

      16.7.3. By Vaccine Type 

      16.7.4. By End Users 

      16.7.5. By Country

   16.8. Prominent Trends 

   16.9. Drivers and Restraints: Impact Analysis 

17. Competition Landscape

   17.1. Competition Dashboard

   17.2. Market Share Analysis By Company (2015)

   17.3. Company Profiles (Details – Overview, Financials, Strategy, Recent Developments)

      17.3.1. GlaxoSmithKline Plc.

      17.3.2. Merck & Co., Inc.

      17.3.3. Pfizer Inc.

      17.3.4. Sanofi

      17.3.5. Pancea Biotec

      17.3.6. Zydua Cadila 

      17.3.7. Emergent BioSolutions Inc.

      17.3.8. Serum Institute of India Pvt. Ltd.

      17.3.9. Bharat Biotech 

      17.3.10. Indian Immunologicals Ltd.

18. Assumptions and Acronyms Used

19. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 01: Global Paediatric Vaccine Market Value (US$ Mn) Forecast By Indication, 2015–2026

Table 02: Global Paediatric Vaccine Market Value (US$ Mn) Forecast By Technology, 2015–2026

Table 03: Global Paediatric Vaccine Market Value (US$ Mn) Forecast By Vaccine Type, 2015–2026

Table 04: Global Paediatric Vaccine Market Value (US$ Mn) Forecast By End Users, 2015–2026

Table 05: North America Paediatric Vaccine Market Value (US$ Mn) Forecast By Country, 2016–2026

Table 06: North America Paediatric Vaccine Market Value (US$ Mn) Forecast By Technology, 2016–2026

Table 07: North America Paediatric Vaccine Market Value (US$ Mn) Forecast By Vaccine Type, 2016–2026

Table 08: North America Balloon Catheter Market Value (US$ Mn) Forecast By Indication, 2016–2026

Table 09: North America Paediatric Vaccine Market Value (US$ Mn) Forecast By End Users, 2016–2026

Table 10: Latin America Pediatric Vaccine Market Value (US$ Mn) Forecast By Country, 2016–2026

Table 11: Latin America Paediatric Vaccine Market Value (US$ Mn) Forecast By Technology, 2016–2026

Table 12: Latin America Paediatric Vaccine Market Value (US$ Mn) Forecast By Vaccine Type, 2016–2026

Table 13: Latin America Paediatric Vaccine Market Value (US$ Mn) Forecast By Indication, 2016–2026

Table 14: Latin America Paediatric Vaccine Market Value (US$ Mn) Forecast By End Users, 2016–2026

Table 15: Eastern Europe Paediatric Vaccine Market Value (US$ Mn) Forecast By Country, 2016–2026

Table 16: Eastern Europe Paediatric Vaccine Market Value (US$ Mn) Forecast By Technology, 2016–2026

Table 17: Eastern Europe Paediatric Vaccine Market Value (US$ Mn) Forecast By Vaccine Type, 2016–2026

Table 18: Eastern Europe Paediatric Vaccine Market Value (US$ Mn) Forecast By Indication, 2016–2026

Table 19: Eastern Europe Paediatric Vaccine Market Value (US$ Mn) Forecast By End Users, 2016–2026

Table 20: Western Europe Paediatric Vaccine Market Value (US$ Mn) Forecast By Country, 2016–2026

Table 21: Western Europe Paediatric Vaccine Market Value (US$ Mn) Forecast By Technology, 2016–2026

Table 22: Western Europe Paediatric Vaccine Market Value (US$ Mn) Forecast By Vaccine Type, 2016–2026

Table 23: Western Europe Paediatric Vaccine Market Value (US$ Mn) Forecast By Indication, 2016–2026

Table 24: Western Europe Paediatric Vaccine Market Value (US$ Mn) Forecast By End Users, 2016–2026

Table 25: Asia Pacific Paediatric Vaccine Market Value (US$ Mn) Forecast By Country, 2016–2026

Table 26: Asia Pacific Paediatric Vaccine Market Value (US$ Mn) Forecast By Technology, 2016–2026

Table 27: Asia Pacific Paediatric Vaccine Market Value (US$ Mn) Forecast By Vaccine Type, 2016–2026

Table 28: Asia Pacific Paediatric Vaccine Market Value (US$ Mn) Forecast By Indication, 2016–2026

Table 29: Asia Pacific Paediatric Vaccine Market Value (US$ Mn) Forecast By End Users, 2016–2026

Table 30: Japan Paediatric Vaccine Market Value (US$ Mn) Forecast By Technology, 2016–2026

Table 31: Japan Paediatric Vaccine Market Value (US$ Mn) Forecast By Vaccine Type, 2016–2026

Table 32: Japan Paediatric Vaccine Market Value (US$ Mn) Forecast By Indication, 2016–2026

Table 33: Japan Paediatric Vaccine Market Value (US$ Mn) Forecast By End Users, 2016–2026

Table 34: Middle East and Africa Paediatric Vaccine Market Value (US$ Mn) Forecast By Country, 2016–2026

Table 35: Middle East and Africa Paediatric Vaccine Market Value (US$ Mn) Forecast By Technology, 2016–2026

Table 36: Middle East and Africa Paediatric Vaccine Market Value (US$ Mn) Forecast By Vaccine Type, 2016–2026

Table 37: Middle East and Africa Pediatric Vaccine Market Value (US$ Mn) Forecast By Indication, 2016–2026

Table 38: Middle East and Africa Paediatric Vaccine Market Value (US$ Mn) Forecast By End Users, 2016–2026

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst
List of Charts

Figure 1: Global Paediatric Vaccine Market Value (US$ Mn) Forecast, 2015–2026 

Figure 2: Global Paediatric Vaccine Market Absolute $ Opportunity, 2015–2026 

Figure 3: Global Paediatric Vaccine Market Y-o-Y Growth, 2015–2026 

Figure above highlights market value, absolute $ opportunity, and Y-o-Y growth rate of the global pediatric vaccine market

Figure 4: Global Paediatric Vaccine Market – Scenario Forecast, 2016–2026 (US$ Mn)

Figure 5: Global Paediatric Vaccine Market share Analysis 2016, By Indication

Figure 6: Global Paediatric Vaccine Market share Analysis 2016, By Vaccine Type 

Figure 7: Global Paediatric Vaccine Market share Analysis 2016, By Technology 

Figure 8: Global Paediatric Vaccine Market Share Analysis (%) By Indication, 2016 & 2026

Figure 9: Global Paediatric Vaccine Market Y-o-Y Growth (%) By Indication, 2016–2026 

Figure 10: Global Paediatric Vaccine Market Y-o-Y Growth (%) By Indication, 2016–2026 

Figure 11: Global Paediatric Vaccine Market Absolute $ Opportunity (US$ Mn) By Pneumococcal Segment, 2016–2026

Figure 12: Global Paediatric Vaccine Market Absolute $ Opportunity (US$ Mn) By DTP Vaccine Segment, 2016–2026

Figure 13: Global Paediatric Vaccine Market Absolute $ Opportunity (US$ Mn) By Rotavirus Vaccine Segment, 2016–2026

Figure 14: Global Paediatric Vaccine Market Absolute $ Opportunity (US$ Mn) By MMR Vaccine Segment, 2016–2026

Figure 15: Global Paediatric Vaccine Market Absolute $ Opportunity (US$ Mn) By Polio Vaccine Segment, 2016–2026

Figure 16: Global Paediatric Vaccine Market Absolute $ Opportunity (US$ Mn) By Influenza Vaccine  Segment, 2016–2026

Figure 17: Global Paediatric Vaccine Market Absolute $ Opportunity (US$ Mn) By Hepatitis B Vaccine  Segment, 2016–2026

Figure 18: Global Paediatric Vaccine Market Absolute $ Opportunity (US$ Mn) By Meningococcal Vaccine Segment, 2016–2026

Figure 19: Global Paediatric Vaccine Market Absolute $ Opportunity (US$ Mn) By Hib Vaccine Segment, 2016–2026

Figure 20: Global Paediatric Vaccine Market Absolute $ Opportunity (US$ Mn) By Varicella Vaccine Segment, 2016–2026

Figure 21: Global Paediatric Vaccine Market Share Analysis (%) By Indication, 2016 & 2026

Figure 22: Global Paediatric Vaccine Market Y-o-Y Growth (%) By technology, 2016–2026 

Figure 23: Global Paediatric Vaccine Market Attractiveness Analysis By Technology, 2016–2026 

Figure 24: Global Paediatric Vaccine Market Absolute $ Opportunity (US$ Mn) By Live or Attenuated Segment, 2016–2026

Figure 25: Global Paediatric Vaccine Market Absolute $ Opportunity (US$ Mn) By Inactivated or Killed Segment, 2016–2026

Figure 26: Global Paediatric Vaccine Market Absolute $ Opportunity (US$ Mn) By Toxoid Vaccine Segment, 2016–2026

Figure 27: Global Paediatric Vaccine Market Absolute $ Opportunity (US$ Mn) By Conjugate Vaccine Segment, 2016–2026

Figure 28: Global Paediatric Vaccine Market Absolute $ Opportunity (US$ Mn) By Subunit Vaccine Segment, 2016–2026

Figure 29: Global Paediatric Vaccine Market Absolute $ Opportunity (US$ Mn) By Recombinant Vaccine  Segment, 2016–2026

Figure 30: Global Paediatric Vaccine Market Share Analysis (%) By Vaccine Type, 2016 & 2026

Figure 31: Global Paediatric Vaccine Market Y-o-Y Growth (%) By Vaccine Type, 2016–2026 

Figure 32: Global Paediatric Vaccine Market Attractiveness Analysis By Vaccine type, 2016–2026 

Figure 33: Global Paediatric Vaccine Market Absolute $ Opportunity (US$ Mn) By Monovalent Segment, 2016–2026

Figure 34: Global Paediatric Vaccine Market Absolute $ Opportunity (US$ Mn) By Multivalent  Segment,  2016–2026

Figure 35: Global Paediatric Vaccine Market Share Analysis (%) By End Users, 2016 & 2026

Figure 36: Global Paediatric Vaccine Market Y-o-Y Growth (%) By End Users, 2016–2026 

Figure 37: Global Paediatric Vaccine Market Attractiveness Analysis By End Users, 2016–2026 

Figure 38: Global Paediatric Vaccine Market Absolute $ Opportunity (US$ Mn) By Hospital Pharmacy Segment, 2016–2026

Figure 39: Global Paediatric Vaccine Market Absolute $ Opportunity (US$ Mn) By Retail Pharmacy Segment, 2016–2026

Figure 40: Global Paediatric Vaccine Market Absolute $ Opportunity (US$ Mn) By Institutional Health Centres Segment, 2016–2026

Figure 41: North America Paediatric Vaccine Market Share Analysis (%) By Country, 2016 & 2026

Figure 42: North America Paediatric Vaccine Market Attractiveness Analysis By Country, 2016–2026

Figure 43: North America Paediatric Vaccine Market Y-o-Y Growth (%) By Country, 2016–2026

Figure 44: North America Paediatric Vaccine Market Attractiveness Analysis By Technology, 2016–2026

Figure 45: North America Paediatric Vaccine Market Attractiveness Analysis By Vaccine Type, 2016–2026

Figure 46: North America Paediatric Vaccine Market Attractiveness Analysis By Indication, 2016–2026

Figure 47: North America Paediatric Vaccine Market Attractiveness Analysis By End Users,  2016–2026

Figure 48: Latin America Paediatric Vaccine Market Share Analysis (%) By Country, 2016 & 2026

Figure 49: Latin America Paediatric Vaccine Market Attractiveness Analysis By Country, 2016–2026

Figure 50: Latin America Paediatric Vaccine Market Y-o-Y Growth (%) By Country, 2016–2026

Figure 51: Latin America Paediatric Vaccine Market Attractiveness Analysis By Technology, 2016–2026

Figure 52: Latin America Paediatric Vaccine Market Attractiveness Analysis By Vaccine Type, 2016–2026

Figure 53: Latin America Paediatric Vaccine Market Attractiveness Analysis By Indication, 2016–2026

Figure 54: Latin America Paediatric Vaccine Market Attractiveness Analysis By End Users,  2016–2026

Figure 55: Eastern Europe Paediatric Vaccine Market Share Analysis (%) By Country, 2016 & 2026

Figure 56: Eastern Europe Paediatric Vaccine Market Attractiveness Analysis By Country, 2016–2026

Figure 57: Eastern Europe Paediatric Vaccine Market Y-o-Y Growth (%) By Country, 2016–2026

Figure 58: Eastern Europe Paediatric Vaccine Market Attractiveness Analysis By Technology, 2016–2026

Figure 59: Eastern Europe Paediatric Vaccine Market Attractiveness Analysis By Vaccine Type, 2016–2026

Figure 60: Eastern Europe Paediatric Vaccine Market Attractiveness Analysis By Indication, 2016–2026

Figure 61: Eastern Europe Paediatric Vaccine Market Attractiveness Analysis By End Users,  2016–2026

Figure 62: Western Europe Paediatric Vaccine Market Share Analysis (%) By Country, 2016 & 2026

Figure 63: Western Europe Paediatric Vaccine Market Attractiveness Analysis By Country, 2016–2026

Figure 64: Western Europe Paediatric Vaccine Market Y-o-Y Growth (%) By Country, 2016–2026

Figure 65: Western Europe Paediatric Vaccine Market Attractiveness Analysis By Technology, 2016–2026

Figure 66: Western Europe Paediatric Vaccine Market Attractiveness Analysis By Vaccine Type, 2016–2026

Figure 67: Western Europe Paediatric Vaccine Market Attractiveness Analysis By Indication, 2016–2026

Figure 68: Western Europe Paediatric Vaccine Market Attractiveness Analysis By End Users,  2016–2026

Figure 69: Asia Pacific Paediatric Vaccine Market Share Analysis (%) By Country, 2016 & 2026

Figure 70: Asia Pacific Paediatric Vaccine Market Attractiveness Analysis By Country, 2016–2026

Figure 71: Asia Pacific Paediatric Vaccine Market Y-o-Y Growth (%) By Country, 2016–2026

Figure 72: Asia Pacific Paediatric Vaccine Market Attractiveness Analysis By Technology, 2016–2026

Figure 73: Asia Pacific Paediatric Vaccine Market Attractiveness Analysis By Vaccine Type, 2016–2026

Figure 74: Asia Pacific Paediatric Vaccine Market Attractiveness Analysis By Indication, 2016–2026

Figure 75: Asia Pacific Paediatric Vaccine Market Attractiveness Analysis By End Users,  2016–2026

Figure 76: Japan Paediatric Vaccine Market Attractiveness Analysis By Technology, 2016–2026

Figure 77: Japan Paediatric Vaccine Market Attractiveness Analysis By Vaccine Type, 2016–2026

Figure 78: Japan Paediatric Vaccine Market Attractiveness Analysis By Indication, 2016–2026

Figure 79: Japan Paediatric Vaccine Market Attractiveness Analysis By End Users,  2016–2026

Figure 80: Middle East and Africa Paediatric Vaccine Market Share Analysis (%) By Country, 2016 & 2026

Figure 81: Middle East and Africa Paediatric Vaccine Market Attractiveness Analysis By Country, 2016–2026

Figure 82: Middle East and Africa Paediatric Vaccine Market Y-o-Y Growth (%) By Country, 2016–2026

Figure 83: Middle East and Africa Paediatric Vaccine Market Attractiveness Analysis By Technology, 2016–2026

Figure 84: Middle East and Africa Paediatric Vaccine Market Attractiveness Analysis By Vaccine Type, 2016–2026

Figure 85: Middle East and Africa Paediatric Vaccine Market Attractiveness Analysis By Indication, 2016–2026

Figure 86: Middle East and Africa Paediatric Vaccine Market Attractiveness Analysis By End Users,  2016–2026

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Paediatric Spasticity Treatment Market

Published : April 2019

Healthcare

Pediatric Nasal Cannula Market

Published : August 2018

Healthcare

Pediatric Measuring Devices Market

Published : November 2017

Healthcare

Pediatric Respiratory Syncytial Virus Infection Market

Published : December 2016

Google translate

Pediatric Vaccine Market